These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 8329714)
1. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Paquette RL; Landaw EM; Pierre RV; Kahan J; Lübbert M; Lazcano O; Isaac G; McCormick F; Koeffler HP Blood; 1993 Jul; 82(2):590-9. PubMed ID: 8329714 [TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368 [TBL] [Abstract][Full Text] [Related]
3. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y Oncology; 1992; 49(2):114-22. PubMed ID: 1574246 [TBL] [Abstract][Full Text] [Related]
4. Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome. de Souza Fernandez T; Menezes de Souza J; Macedo Silva ML; Tabak D; Abdelhay E Leuk Res; 1998 Feb; 22(2):125-34. PubMed ID: 9593469 [TBL] [Abstract][Full Text] [Related]
6. Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value. Constantinidou M; Chalevelakis G; Economopoulos T; Koffa M; Liloglou T; Anastassiou C; Yalouris A; Spandidos DA; Raptis S Ann Hematol; 1997 Jan; 74(1):11-4. PubMed ID: 9031609 [TBL] [Abstract][Full Text] [Related]
7. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Vasioukhin V; Anker P; Maurice P; Lyautey J; Lederrey C; Stroun M Br J Haematol; 1994 Apr; 86(4):774-9. PubMed ID: 7918071 [TBL] [Abstract][Full Text] [Related]
8. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Neubauer A; Dodge RK; George SL; Davey FR; Silver RT; Schiffer CA; Mayer RJ; Ball ED; Wurster-Hill D; Bloomfield CD Blood; 1994 Mar; 83(6):1603-11. PubMed ID: 8123851 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347 [TBL] [Abstract][Full Text] [Related]
10. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Padua RA; Guinn BA; Al-Sabah AI; Smith M; Taylor C; Pettersson T; Ridge S; Carter G; White D; Oscier D; Chevret S; West R Leukemia; 1998 Jun; 12(6):887-92. PubMed ID: 9639416 [TBL] [Abstract][Full Text] [Related]
11. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969 [TBL] [Abstract][Full Text] [Related]
12. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258 [TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108 [TBL] [Abstract][Full Text] [Related]
14. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia. Venkatraj VS; Gaidano G; Auerbach AD Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673 [TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of ras gene activation in myeloid leukemic cells. Lübbert M; Jonas D; Miller CW; Herrmann F; Mertelsmann R; McCormick F; Koeffler HP Oncogene; 1990 Apr; 5(4):583-7. PubMed ID: 2183160 [TBL] [Abstract][Full Text] [Related]
16. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077 [TBL] [Abstract][Full Text] [Related]
17. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Lyons J; Janssen JW; Bartram C; Layton M; Mufti GJ Blood; 1988 Jun; 71(6):1707-12. PubMed ID: 3285909 [TBL] [Abstract][Full Text] [Related]
18. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864 [TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082 [TBL] [Abstract][Full Text] [Related]
20. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Neubauer A; Greenberg P; Negrin R; Ginzton N; Liu E Leukemia; 1994 Apr; 8(4):638-41. PubMed ID: 7512175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]